Results

1–7 of 7 results for Andrew A. Moshfeghi

Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
Vitreoretinal Interface Disease In the Setting of AMD
Andrew A. Moshfeghi, MD, MBA, FASRS
Updates from the Field
2019
How to Approach Proliferative Diabetic Retinopathy in 2020
Andrew A. Moshfeghi, MD, MBA, FASRS
Updates from the Field
2019
Outcomes of Antivascular Endothelial Growth Factor (VEGF) Therapy for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice
Andrew A. Moshfeghi, MD, MBA, FASRS
Annual Meeting Talks
2018
Macula-Sparing GRT RRD
Andrew A. Moshfeghi, MD, MBA, FASRS
Retina Image Bank: Images of the Week
2017
Intravitreal Injections: Logistics, Safety, and Pearls
Andrew A. Moshfeghi, MD, MBA, FASRS
Webinars and Journal Clubs
2018